- Home
- POAS vs STTK Comparison
POAS vs STTK Comparison
Compare POAS & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | POAS | STTK |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.0M | 119.0M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | POAS | STTK |
|---|---|---|
| Price | $3.66 | $3.14 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 499.9K | 328.1K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $128,328.00 | ★ $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.98 | $0.69 |
| 52 Week High | $4.30 | $3.38 |
Technical Indicators
Market Signals| Indicator | POAS | STTK |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 71.00 |
| Support Level | N/A | $1.93 |
| Resistance Level | N/A | $3.30 |
| Average True Range (ATR) | 0.00 | 0.23 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 0.00 | 80.69 |
Price Performance
Historical ComparisonAbout STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.